Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
Taru Hallinen,1 Erkki Soini,1 Christian Asseburg,1 Miika Linna,2 Pia Eloranta,3 Sari Sintonen,3 Mikko Kosunen3 1ESiOR Oy, Kuopio, Finland; 2Aalto University, Department of Industrial Engineering and Management, Espoo, Finland; 3Pfizer Oy, Helsinki, FinlandCorrespondence: Taru Hallinen ESiOR Oy, Tull...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-08-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cost-effectiveness-of-apixaban-versus-other-direct-oral-anticoagulants-peer-reviewed-fulltext-article-CEOR |
| _version_ | 1819093795901276160 |
|---|---|
| author | Hallinen T Soini E Asseburg C Linna M Eloranta P Sintonen S Kosunen M |
| author_facet | Hallinen T Soini E Asseburg C Linna M Eloranta P Sintonen S Kosunen M |
| author_sort | Hallinen T |
| collection | DOAJ |
| description | Taru Hallinen,1 Erkki Soini,1 Christian Asseburg,1 Miika Linna,2 Pia Eloranta,3 Sari Sintonen,3 Mikko Kosunen3 1ESiOR Oy, Kuopio, Finland; 2Aalto University, Department of Industrial Engineering and Management, Espoo, Finland; 3Pfizer Oy, Helsinki, FinlandCorrespondence: Taru Hallinen ESiOR Oy, Tulliportinkatu 2 LT4, Kuopio, FI-70100, FinlandTel +358 50 568 1894Email taru.hallinen@esior.fiPurpose: Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in Finland. DOACs have been shown to be cost-effective in comparison to warfarin, but published evidence of relative cost-effectiveness between DOACs is still scarce and mostly based on indirect comparisons of clinical trial evidence. The aim of this study was to compare the cost-effectiveness of apixaban to dabigatran, rivaroxaban and warfarin in a Finnish setting using real-life evidence where available.Patients and Methods: A lifetime Markov simulation model used previously in a published Finnish assessment comparing apixaban and warfarin was modified and updated with the relative effectiveness and safety data available from the real-world NAXOS-study and representative Finnish input data for patient characteristics, event risks, mortality, resource use, costs, and quality of life. Apixaban’s cost-effectiveness was assessed from health care payer perspective (using 3% per year discount rate) based on incremental cost-effectiveness ratio (ICER, cost per quality-adjusted life year [QALY] gained), probability of cost-effectiveness (at willingness-to-pay [WTP] of 35,000 euros/QALY), and net monetary benefit (NMB).Results: Apixaban increased the average modelled quality-adjusted life-expectancy and reduced the average total health care costs of AF patients when compared to warfarin (+0.14 QALYs, − 3691 euros), dabigatran (+0.11 QALYs, − 404 euros), and rivaroxaban (+0.03 QALYs, − 43 euros). The resulting NMB of apixaban versus warfarin, dabigatran and rivaroxaban was 8723, 4168, and 1129 euros, respectively. The respective probabilities of apixaban being cost-effective against each comparator were 100%, 92.7%, and 64.0%.Conclusion: In this modelling study, apixaban dominated other anticoagulants in the Finnish real-life setting.Keywords: apixaban, cost-utility, dabigatran, economic evaluation, rivaroxaban, warfarin |
| first_indexed | 2024-12-21T23:17:12Z |
| format | Article |
| id | doaj.art-4cd121d72b8f4fdd8096b162bb80643a |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-21T23:17:12Z |
| publishDate | 2021-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-4cd121d72b8f4fdd8096b162bb80643a2022-12-21T18:46:53ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812021-08-01Volume 1374575567835Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial FibrillationHallinen TSoini EAsseburg CLinna MEloranta PSintonen SKosunen MTaru Hallinen,1 Erkki Soini,1 Christian Asseburg,1 Miika Linna,2 Pia Eloranta,3 Sari Sintonen,3 Mikko Kosunen3 1ESiOR Oy, Kuopio, Finland; 2Aalto University, Department of Industrial Engineering and Management, Espoo, Finland; 3Pfizer Oy, Helsinki, FinlandCorrespondence: Taru Hallinen ESiOR Oy, Tulliportinkatu 2 LT4, Kuopio, FI-70100, FinlandTel +358 50 568 1894Email taru.hallinen@esior.fiPurpose: Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in Finland. DOACs have been shown to be cost-effective in comparison to warfarin, but published evidence of relative cost-effectiveness between DOACs is still scarce and mostly based on indirect comparisons of clinical trial evidence. The aim of this study was to compare the cost-effectiveness of apixaban to dabigatran, rivaroxaban and warfarin in a Finnish setting using real-life evidence where available.Patients and Methods: A lifetime Markov simulation model used previously in a published Finnish assessment comparing apixaban and warfarin was modified and updated with the relative effectiveness and safety data available from the real-world NAXOS-study and representative Finnish input data for patient characteristics, event risks, mortality, resource use, costs, and quality of life. Apixaban’s cost-effectiveness was assessed from health care payer perspective (using 3% per year discount rate) based on incremental cost-effectiveness ratio (ICER, cost per quality-adjusted life year [QALY] gained), probability of cost-effectiveness (at willingness-to-pay [WTP] of 35,000 euros/QALY), and net monetary benefit (NMB).Results: Apixaban increased the average modelled quality-adjusted life-expectancy and reduced the average total health care costs of AF patients when compared to warfarin (+0.14 QALYs, − 3691 euros), dabigatran (+0.11 QALYs, − 404 euros), and rivaroxaban (+0.03 QALYs, − 43 euros). The resulting NMB of apixaban versus warfarin, dabigatran and rivaroxaban was 8723, 4168, and 1129 euros, respectively. The respective probabilities of apixaban being cost-effective against each comparator were 100%, 92.7%, and 64.0%.Conclusion: In this modelling study, apixaban dominated other anticoagulants in the Finnish real-life setting.Keywords: apixaban, cost-utility, dabigatran, economic evaluation, rivaroxaban, warfarinhttps://www.dovepress.com/cost-effectiveness-of-apixaban-versus-other-direct-oral-anticoagulants-peer-reviewed-fulltext-article-CEORapixabancost-utilitydabigatraneconomic evaluationrivaroxabanwarfarin |
| spellingShingle | Hallinen T Soini E Asseburg C Linna M Eloranta P Sintonen S Kosunen M Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation ClinicoEconomics and Outcomes Research apixaban cost-utility dabigatran economic evaluation rivaroxaban warfarin |
| title | Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation |
| title_full | Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation |
| title_fullStr | Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation |
| title_full_unstemmed | Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation |
| title_short | Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation |
| title_sort | cost effectiveness of apixaban versus other direct oral anticoagulants and warfarin in the prevention of thromboembolic complications among finnish patients with non valvular atrial fibrillation |
| topic | apixaban cost-utility dabigatran economic evaluation rivaroxaban warfarin |
| url | https://www.dovepress.com/cost-effectiveness-of-apixaban-versus-other-direct-oral-anticoagulants-peer-reviewed-fulltext-article-CEOR |
| work_keys_str_mv | AT hallinent costeffectivenessofapixabanversusotherdirectoralanticoagulantsandwarfarininthepreventionofthromboemboliccomplicationsamongfinnishpatientswithnonvalvularatrialfibrillation AT soinie costeffectivenessofapixabanversusotherdirectoralanticoagulantsandwarfarininthepreventionofthromboemboliccomplicationsamongfinnishpatientswithnonvalvularatrialfibrillation AT asseburgc costeffectivenessofapixabanversusotherdirectoralanticoagulantsandwarfarininthepreventionofthromboemboliccomplicationsamongfinnishpatientswithnonvalvularatrialfibrillation AT linnam costeffectivenessofapixabanversusotherdirectoralanticoagulantsandwarfarininthepreventionofthromboemboliccomplicationsamongfinnishpatientswithnonvalvularatrialfibrillation AT elorantap costeffectivenessofapixabanversusotherdirectoralanticoagulantsandwarfarininthepreventionofthromboemboliccomplicationsamongfinnishpatientswithnonvalvularatrialfibrillation AT sintonens costeffectivenessofapixabanversusotherdirectoralanticoagulantsandwarfarininthepreventionofthromboemboliccomplicationsamongfinnishpatientswithnonvalvularatrialfibrillation AT kosunenm costeffectivenessofapixabanversusotherdirectoralanticoagulantsandwarfarininthepreventionofthromboemboliccomplicationsamongfinnishpatientswithnonvalvularatrialfibrillation |